Compass Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
CMPX$0.84+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
(In thousands)
| Common Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated · Total Stockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income | Deficit | Equity | |
| Balance at December 31, 2023 | 127,668 | $13 | $463,796 | $37 | $(315,308) | $148,538 |
| Common stock issued in ATM offering, net of costs of $0.5million | 9,790 | 1 | 17,568 | — | — | 17,569 |
| Stock-based awards, net of tax remittance | 362 | — | (232) | — | — | (232) |
| Stock-based compensation | — | — | 8,560 | — | — | 8,560 |
| Unrealized gain on marketable securities | — | — | — | 173 | — | 173 |
| Net loss | — | — | — | — | (49,375) | (49,375) |
| Balance at December 31, 2024 | 137,820 | 14 | $489,692 | $210 | $(364,683) | $125,233 |
| Common stock and warrants issued, net of costs of $8.6 million | 39,290 | $4 | $129,357 | $— | $— | $129,361 |
| Common stock issued upon exercise of options | 545 | — | 1,275 | — | — | 1,275 |
| Stock-based awards, net of tax remittance | 669 | — | (1,027) | — | — | (1,027) |
| Stock-based compensation | — | — | 8,368 | — | — | 8,368 |
| Unrealized gain on marketable securities | — | — | — | 70 | — | 70 |
| Net loss | — | — | — | — | (66,489) | (66,489) |
| Balance at December 31, 2025 | 178,324 | $18 | $627,665 | $280 | $(431,172) | $196,791 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.